Ö.Kütük; "Akt and Mitochondrial Priming: Targeting PTEN-null Cancer...
  • FENS
  • Ö.Kütük; "Akt and Mitochondrial Priming: Targeting PTEN-null Cancer...

You are here

Faculty of Engineering and Natural Sciences


Akt and mitochondrial priming: targeting PTEN-null cancer cells
 Özgür Kütük Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston,
Alterations in PI3K/Akt pathway are frequently found in human cancer.  PTEN is a lipid phosphatase that selectively dephosphorylates phosphoinositides and opposes the effects of PI3K. Loss or inactivating mutations of PTEN results in constitutive activation of PI3K/Akt pathway. Considering its prosurvival effect, targeting PI3K/Akt pathway can sensitize cancer cells to programmed cell death.  In our studies, we investigated the regulation of mitochondrial priming by Akt signaling in PTEN-null cancer cells.  Our results underscore the direct role of Akt in the regulation of mitochondrial cell death and sensitivity to Bcl-2 inhibition in PTEN-null cancer cells.  
Özgür Kütük got his MD degree from Marmara University School of Medicine in 2000 and his PhD degree from Sabanci University Biological Sciences and Bioengineering Program in 2006. During his PhD education, he was granted fellowships from FEBS and EACR to wotk as a visiting scientist at Karolinska Center for Cancer. He started his postdoctoral fellowship in Dana-Farber Cancer Institute at Harvard Medical School in 2006 and currently works as Terri Brodeur Breast Cancer Foundation Fellow in Dr. Anthony Letai’s lab at DFCI/HMS.  
September 22, 2010, 12:40, FENS G032